Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | KIF11 | P52732 | 7/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4570566 | 1.00 | CA4 (0.56) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL12459850 | 0.92 | ACHE (0.58) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL3098811 | 0.91 | CA1 (0.61) | CA4LTA4HCA12CA1CA2 | |
| SCHEMBL24258459 | 0.90 | ESR1 (0.47) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL16591527 | 0.90 | ESR2 (0.74) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL20878780 | 0.90 | ESR1 (0.47) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL18127940 | 0.87 | CA4 (0.52) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL2689280 | 0.86 | CA4 (0.56) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL15628358 | 0.86 | KIF11 (0.43) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL13054813 | 0.86 | KIF11 (0.46) | CA4ESR1ESR2LTA4HKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115710165-B | Method for preparing 4,4' -dimethoxy trityl chloride by utilizing oligonucleotide synthesis waste liquid | 北京擎科生物科技有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-115710165-A | Method for preparing 4,4' -bis (methoxy) trityl chloride by using oligonucleotide synthesis waste liquid | 北京擎科生物科技有限公司 | 2023-02-24 | — | — | CN | claimed |
| WO-2025137730-A1 | N-SUBSTITUTED TRYPTAMINES AND N-SUBSTITUTED LYSERGAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| WO-2024006477-A1 | MULTIPLEX DYE COMPOUNDS | Life Technologies Corporation (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230312630-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | AARHUS UNIVERSITET (DK) | 2023-10-05 | — | — | US | disclosed |
| WO-2023186842-A1 | SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-10-05 | — | — | WO | disclosed |
| US-20230304932-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS INVOLVING ENERGY TRANSFER DYE CONJUGATES AND ANALYTES COMPRISING THE SAME | Life Technologies Corporation | 2023-09-28 | — | — | US | disclosed |
| US-20230304932-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS INVOLVING ENERGY TRANSFER DYE CONJUGATES AND ANALYTES COMPRISING THE SAME | Life Technologies Corporation | 2023-09-28 | — | — | US | disclosed |
| US-20070123713-A1 | Polycyclic dihydroxy compound and methods for preparation | CITIBANK, N.A., AS COLLATERAL AGENT | 2007-05-31 | — | — | US | disclosed |
| US-20070123682-A1 | Polycarbonates, polyesters, polycarbonateesters, polyurethanes and epoxy resins prepared from monomers including N-4-[1,1'-di(p-hydroxyphenyl)ethyl]phenyl phthalimide or derivatives; articles with improved chemical resistance and high glass transition temperatures and refractive indices | SABIC GLOBAL TECHNOLOGIES IP B.V. (NL) | 2007-05-31 | — | — | US | disclosed |
| US-20070082349-A1 | Photocrosslinking probes and uses of the same | NORTH CAROLINA STATE OF UNIVERSITY | 2007-04-12 | — | — | US | disclosed |
| US-20070082349-A1 | Photocrosslinking probes and uses of the same | NORTH CAROLINA STATE OF UNIVERSITY | 2007-04-12 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2007014348-A2 | PHOTOCROSSLINKING PROBES AND USES OF THE SAME | NORTH CAROLINA UNIVERSITY (US) | 2007-02-01 | — | — | WO | disclosed |
| EP-0703498-B1 | Photosensitive resin composition and method for forming a photoresist pattern | MITSUBISHI CHEM CORP (JP) | 1997-12-29 | — | — | EP | disclosed |
| US-5698362-A | CONTAINING A TRIARYLMETHANE DERIVATIVE; HIGH RESOLUTION, EXCELLENT IN DEPTH OF FOCUS AND PATTERN PROFILE, STORAGE STABLE | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0703498-A1 | Photosensitive resin composition and method for forming a photoresist pattern | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | RNASEH1, RNASE1, DNASE1 | CA4 2919/4885ESR1 4531/4885ESR2 3934/4885 |
| US-20230312630-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | RNGTT, PPA1, PNP | CA4 3126/4885ESR1 2815/4885ESR2 4019/4885 |
| US-20070082349-A1 | Photocrosslinking probes and uses of the same | DCLRE1A, LIG4, LIG1 | CA4 3774/4885ESR1 2250/4885ESR2 3148/4885 |
| US-20070123713-A1 | Polycyclic dihydroxy compound and methods for preparation | PAH, DDT, CYP24A1 | CA4 478/4885ESR1 554/4885ESR2 1183/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | CA4 4429/4885ESR1 3041/4885ESR2 3204/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | CA4 3164/4885ESR1 664/4885ESR2 929/4885 |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | CA4 4512/4885ESR1 2919/4885ESR2 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.